Clinical Trials
10 trialsNCT05186753 2026-05-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT01701843 2025-02-24
Cromoglicate in Mastocytosis
LEO Pharma
Phase 2 Terminated
NCT04333108 2023-05-06
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
AB Science
Phase 3 Unknown
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT02808793 2019-03-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Allakos Inc.
Phase 1 Completed
NCT00831974 2018-12-11
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
AB Science
Phase 2 Completed
NCT01266369 2018-12-10
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
AB Science
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT02478957 2016-09-29
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Phase 2 Completed